Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges

Lara el Hayderi, Fany Colson, Bita Dezfoulian, Arjen F Nikkels Department of Dermatology, CHU du Sart Tilman, University Hospital of Liège, Liège, Belgium Abstract: As TNF-α is a major factor in the immune defense against herpes zoster (HZ); an increased incidence and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	el Hayderi L, Colson F, Dezfoulian B, Nikkels AF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	herpes zoster TNF antagonists anti-IL17 anti-IL12/23 psoriasis aciclovir. Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/7bae1aeb098940b7a77500dd42419f0d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7bae1aeb098940b7a77500dd42419f0d
record_format	dspace
spelling	oai:doaj.org-article:7bae1aeb098940b7a77500dd42419f0d2021-12-02T06:54:21ZHerpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges2230-326Xhttps://doaj.org/article/7bae1aeb098940b7a77500dd42419f0d2016-10-01T00:00:00Zhttps://www.dovepress.com/herpes-zoster-in-psoriasis-patients-undergoing-treatment-with-biologic-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XLara el Hayderi, Fany Colson, Bita Dezfoulian, Arjen F Nikkels Department of Dermatology, CHU du Sart Tilman, University Hospital of Liège, Liège, Belgium Abstract: As TNF-α is a major factor in the immune defense against herpes zoster (HZ); an increased incidence and severity of HZ cases were suspected in patients undergoing treatment with TNF antagonists. Several studies and clinical experience provided evidence that the incidence of HZ increases by twofold to threefold in this patient category. The number of severe cases of HZ, with multisegmental, disseminated cutaneous, and/or systemic involvement, is also increased. Concerning psoriasis patients under biologicals, the clinician should be more alert for an eventual HZ event, in particular during the first year of biological treatment, and be aware of the possibility of more severe HZ cases. HZ may also undergo an age-shift toward younger patients. Rapid identification of risk factors for severe HZ, such as severe prodromal pains and/or the presence of satellite lesions, is recommended. The treatment recommendations of HZ in this patient group are identical to the recently published guidelines for the management of HZ. The live attenuated viral vaccine OKA/Merck strain anti-HZ vaccination is recommended before initiating biological treatment in psoriasis patients. The new adjuvanted anti-HZ vaccine will probably also benefit patients while on biological treatment. Keywords: herpes zoster, TNF antagonists, anti-IL17, anti-IL12/23, psoriasis, aciclovirel Hayderi LColson FDezfoulian BNikkels AFDove Medical Pressarticleherpes zosterTNF antagonistsanti-IL17anti-IL12/23psoriasisaciclovir.DermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 6, Pp 145-151 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	herpes zoster TNF antagonists anti-IL17 anti-IL12/23 psoriasis aciclovir. Dermatology RL1-803
spellingShingle	herpes zoster TNF antagonists anti-IL17 anti-IL12/23 psoriasis aciclovir. Dermatology RL1-803 el Hayderi L Colson F Dezfoulian B Nikkels AF Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges
description	Lara el Hayderi, Fany Colson, Bita Dezfoulian, Arjen F Nikkels Department of Dermatology, CHU du Sart Tilman, University Hospital of Liège, Liège, Belgium Abstract: As TNF-α is a major factor in the immune defense against herpes zoster (HZ); an increased incidence and severity of HZ cases were suspected in patients undergoing treatment with TNF antagonists. Several studies and clinical experience provided evidence that the incidence of HZ increases by twofold to threefold in this patient category. The number of severe cases of HZ, with multisegmental, disseminated cutaneous, and/or systemic involvement, is also increased. Concerning psoriasis patients under biologicals, the clinician should be more alert for an eventual HZ event, in particular during the first year of biological treatment, and be aware of the possibility of more severe HZ cases. HZ may also undergo an age-shift toward younger patients. Rapid identification of risk factors for severe HZ, such as severe prodromal pains and/or the presence of satellite lesions, is recommended. The treatment recommendations of HZ in this patient group are identical to the recently published guidelines for the management of HZ. The live attenuated viral vaccine OKA/Merck strain anti-HZ vaccination is recommended before initiating biological treatment in psoriasis patients. The new adjuvanted anti-HZ vaccine will probably also benefit patients while on biological treatment. Keywords: herpes zoster, TNF antagonists, anti-IL17, anti-IL12/23, psoriasis, aciclovir
format	article
author	el Hayderi L Colson F Dezfoulian B Nikkels AF
author_facet	el Hayderi L Colson F Dezfoulian B Nikkels AF
author_sort	el Hayderi L
title	Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges
title_short	Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges
title_full	Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges
title_fullStr	Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges
title_full_unstemmed	Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges
title_sort	herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/7bae1aeb098940b7a77500dd42419f0d
work_keys_str_mv	AT elhayderil herpeszosterinpsoriasispatientsundergoingtreatmentwithbiologicalagentsprevalenceimpactandmanagementchallenges AT colsonf herpeszosterinpsoriasispatientsundergoingtreatmentwithbiologicalagentsprevalenceimpactandmanagementchallenges AT dezfoulianb herpeszosterinpsoriasispatientsundergoingtreatmentwithbiologicalagentsprevalenceimpactandmanagementchallenges AT nikkelsaf herpeszosterinpsoriasispatientsundergoingtreatmentwithbiologicalagentsprevalenceimpactandmanagementchallenges
_version_	1718399699366445056

Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges

Ejemplares similares